Patient Blood Management in Elective Total Hip- and Knee-replacement Surgery (Part 2): A Randomized Controlled Trial on Blood Salvage as Transfusion Alternative Using a Restrictive Transfusion Policy in Patients with a Preoperative Hemoglobin above 13 g/dl
So-Osman, Cynthia M.D., Ph.D.,
M.Sc.; Nelissen, Rob G. H. H. M.D., Ph.D.; Koopman-van Gemert, Ankie W.
M. M. M.D., Ph.D.; Kluyver, Ewoud M.D.; Pöll, Ruud G. M.D., Ph.D.;
Onstenk, Ron M.D.; Van Hilten, Joost A. Ph.D.; Jansen-Werkhoven, Thekla
M. Ph.D.; van den Hout, Wilbert B. Ph.D.; Brand, Ronald Ph.D.; Brand,
Anneke M.D., Ph.D.
Anesthesiology:
In this prospective randomized
controlled trial including 1,759 patients with a preoperative hemoglobin
level greater than 13 g/dl (and therefore ineligible for
erythropoietin) undergoing hip or knee arthroplasty, autologous intra-
and postoperative blood salvage devices were not effective as
transfusion alternatives. The use of these devices did not reduce
erythrocyte use and increased costs.
Anesthesiology:
In this prospective randomized
controlled trial including 1,759 patients with a preoperative hemoglobin
level greater than 13 g/dl (and therefore ineligible for
erythropoietin) undergoing hip or knee arthroplasty, autologous intra-
and postoperative blood salvage devices were not effective as
transfusion alternatives. The use of these devices did not reduce
erythrocyte use and increased costs.
No comments:
Post a Comment